Introduction
Māori are overrepresented in cardiovascular disease (CVD) mortality and morbidity statistics. 1 For example, the mortality from coronary heart disease among Māori in New Zealand (NZ) is three to four times higher than in the general population. 2 Cardiovascular risk (CVR) factors are particularly prevalent in Māori, including smoking, higher blood pressure (BP) and increased cholesterol levels; 3 moreover, after adjusting for age and sex differences, Māori adults have been shown to be 1.3 times as likely as non-Māori to be taking medication for hypertension, and diabetes prevalence among Māori is 7%. 4 A Māori-led primary health organisation (PHO) found that Māori were significantly more likely to have high CVR than non-Māori, and that 66% of those with either diabetes or established CVD were not meeting blood pressure or lipid management recommendations. 5 Despite the inequity and disparities being well recognised, a 2007 national survey of district health boards (DHBs) and PHOs highlighted the struggle to put equity QUANTITATIVE RESEARCH
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What we already know: Cardiovascular disease (CVD) is one of the leading causes of death and disability in the world. New Zealand (NZ) Māori have a higher risk for CVD and a higher disease mortality rate than the general NZ population.
What this study adds: Māori patients have the lowest CVR assessment rate, compared to Pacific people and non-Māori/non-Pacific patients, but are more likely to have a high CVR. There are substantial levels of poor medication adherence, particularly for cholesterol-lowering medication. The association between CVD medication adherence and CVR factors suggests that general practices should do more to actively support medication adherence in Māori.
principles into practice, with the populations that conventional practitioners find hard to reach being often underserved. 6 In light of their increased risk, NZ clinical practice guidelines recommend CVR assessment be undertaken in Māori 10 years earlier than for Pākehā (NZ Europeans):
• age 35+ for Māori, Pacific or Indo-Asian men; • 45+ for Māori, Pacific, Indo-Asian women and men of non-Māori/non-Pacific/non-Indo-Asian ethnicities; and • 55+ for women of non-Māori/non-Pacific/ non-Indo-Asian ethnicities. 7 There are data suggesting that more than 70% of eligible (i.e. guideline-indicated) NZ adults have had their CVR assessed; 8 and 64.7% of the eligible Māori population have completed a CVR assessment within the past five years. 9 However, the CVR assessment rate across the eligible NZ population varies from DHB to DHB, ranging from 19.8% to 66.2%, with the national average being 49%. 10 In terms of CVR management interventions, studies have found good efficacy rates of anti hypertensive medications in reducing cardiovascular and renal events. [11] [12] [13] [14] However, low medication adherence is a significant obstacle to CVR management, with adherence approaching only 50%, particularly among lower socioeconomic groups. 15, 16 The Caring Does Matter (CDM) initiative (May 2012 to August 2013) was a programme funded by the NZ Ministry of Health Pacific Development Fund and aimed at improving adherence to CVD medication to lower CVR among Pacific people at high risk of CVD. 17 Fourteen general practices in Auckland and two practices in Northland participated in CDM. The CDM programme identified high-CVR patients and their CVD medication adherence status, through examining their electronic medical records (EMR) in general practice. This paper presents analysis of CVR management among Māori, utilising the CDM baseline data (including ethnicity information recorded in the practices' EMR). A profile of CVR management in Pacific people 18 and of the CDM intervention protocol 17 have been published elsewhere.
Methods
The study was approved by the Northern X 19 ). The Pacific group is analysed separately from other non-Māori ethnicities due to the high Pacific caseload in this study, which, if combined with other ethnicities in the analysis, would give a biased representation of the general non-Māori population in NZ. Prioritised ethnicity was used for defining which patients were Māori in the dataset, in keeping with the NZ Ministry of Health protocols for ethnicity data reporting. 20 Those whose EMR identified them as both Māori and Pacific among the three ethnicity codes were considered Māori in this analysis.
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Data collected from the EMR could be matched to individuals by the practices for structured care of their own patients, but were de-identified for use in aggregate analysis by the researchers. The data included ethnicity, age, and gender; CVR screening results in the past five years; prescriptions over the past two years; and physiological measures of CVR factors, including BP (using the mean of the three most recent readings in the past five years), lipids and HbA1c (both using the most recent result over the past five years).
The CVR scores in the EMR are calculated using a range of products that integrate with the practice EMR systems and that are routinely employed by NZ general practices, including PREDICT TM 21 and BestPractice. 22 These products are based on variations of the Framingham model, 23 taking into account risk factors such as age and BP, with an increase in CVR of 5% added for Māori, Pacific and Indo-Asian people. For the present study, 'high CVR' is taken as constituting a five-year risk of a CVD event ≥15%, which in accordance with NZ CVD guidelines is the recommended threshold for drug treatment. 7 When a patient had multiple CVR assessments within the five-year period of data analysed, the most recent CVR assessment was used.
Determination of 'poor' or 'low' adherence to CVD medication was based on medication supply, as indicated in the most recent two years of EMR prescription data. Poor adherence was defined as medication possession ratio 24 (MPR; percent of days covered with a prescription) of less than 80% over the past 15 months, or with no prescription in the past six months. Adherence was calculated for antihypertensive, cholesterol and oral antidiabetic medications for patients with at least one prescription of that class over nine months (the 'run-in' period) prior to the five quarters immediately before baseline data collection. Patients without a prescription in the run-in period were excluded from judgment as 'low' or 'high' adherers, and were either considered as 'not treated', or a 'recent start' for a given medication class (the latter category was used if there were some prescriptions of that class in the recent 15 months). Code specific to the CDM programme was written using the SAS software package, Version 9.2 (SAS Institute Inc., Cary, North Carolina), to calculate MPR and to identify CVR management gaps (e.g. high CVR but low MPR, or no CVR recorded despite being of guideline-indicated age/ethnicity combination). The code adapted algorithms previously developed for quality audit of chronic condition management, 25 and for an earlier Pacific medication adherence promotion trial. 26 Patient data were de-identified and analysed by ethnic group (Māori, Pacific, and non-Māori/ non-Pacific) for the rate of CVR screening and CVR scores, treatment patterns (including rates of medication adherence), and physiological measures, including systolic blood pressure (SBP); diastolic blood pressure (DBP); HbA1c; and total cholesterol to HDL cholesterol ratio (TC/HDL) results, for those with high CVR. Statistical analyses used include normality tests, Chi-square tests, Kruskal-Wallis tests and Wilcoxon-MannWhitney U tests, with a significance level used in these analyses of 0.05. The median value and interquartile range (IQR) are reported for data not normally distributed; and the p-value is reported for all tests of significance.
Results
CVR assessment and scores in Māori, Pacific and non-Māori/non-Pacific
The EMR records included 38 174 women (5684 Māori) and 34 177 men (4674 Māori). Ethnicity data was recorded in 99.9% of these patients. A lower proportion of Māori, as compared to Pacific or non-Māori/non-Pacific patients, had an assessed CVR in the ≥20 age group and in the guideline-indicated age groups (Chi-square test, both p<0.0001, see also Table 1 ). Of those who had their CVR assessed, a higher proportion of Māori (38%) were found to have high CVR than Pacific people (34%) and non-Māori/non-Pacific people (30%); they were also younger. The median age for Māori with high CVR was 61 years, compared to 63 years for Pacific patients and 68 years for non-Māori/non-Pacific people.
Treatment of Māori, Pacific and nonMāori/non-Pacific patients with high CVR
The proportion of Māori patients in the high-CVR group being treated with oral antidiabetic QUANTITATIVE RESEARCH ORIGINAL SCIENTIFIC PAPER Table 4 provides a summary of physiological measures by ethnicity.
Physiological measures and medication adherence in Māori with high CVR
The Māori patients with high CVR who were prescribed antihypertensive medications in the last two years (irrespective of their adherence status) were found to have a higher median SBP than those not prescribed treatment. No significant difference in median DBP was found according to treatment status. A significantly lower median TC/HDL in Māori patients with high CVR who were prescribed cholesterollowering medications was observed, and a significantly higher median HbA1c in those prescribed with oral antidiabetic medication ( Table 5) . Among Māori patients with high CVR who were treated, adherers had better results (lower SBP, DBP, TC/HDL and HbA1c) than non-adherers (Table 6 ).
Discussion
In an opportunistic assessment of a large cohort of Māori general practice patients in Auckland and Northland, we have found substantial oppor-
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ORIGINAL SCIENTIFIC PAPER tunities for improved management of CVR. One area for improvement is in CVR assessment: 54% of Māori, 40% of Pacific and 46% of non-Māori/ non-Pacific patients who were indicated for CVR assessment lacked an identifiable CVR assessment within the past five years (46% overall across ethnicities). This overall CVR assessment rate is slightly higher than the national average of 49% reported in the Ministry's 2011/12 Quarter Four figure (contemporary with the study data extraction time), 10 but still has ample room for improvement, particularly for Māori. Support has been provided by the Ministry of Health for CVR assessment activity, which is now used as a quality indicator. The Ministry of Health has set a target for DHBs to achieve 90% CVR assessment for indicated adults by July 2014. 27 Improvement in the assessment rate has been observed in recent audits, reaching 73% across all DHBs by the end of 2013. 28 A higher proportion of Māori adults in our analysis were found to have high CVR, compared to non-Māori. Amongst those patients who were assessed and found to have a high CVR, unsurprisingly many had physiological measures well above desirable levels, based on their most recent readings. For example, fewer than half of patients assessed with a high CVR had achieved an SBP of 130 mmHg or lower, averaged over the last three readings. Moreover, there were substantial levels of poor medication adherence, particularly for cholesterol-lowering medication. The association between poor CVD medication adherence and poor CVD outcomes has been highlighted in the literature. 29 The significant association between CVD medication adherence and levels of related physiological measurements (BP, cholesterol and HbA1c) found in the present study suggests that practices should further support medication adherence as part of improved CVR management.
The profile of CVR management in Pacific people, including the medication adherence gaps in the high-CVR patients, has been reported previously;
18 the widened analysis in the current article highlights similar challenges for Māori. A number of key reports have already identified ways forward in meeting the challenge. The National Māori Health Action Plan recommends a stronger primary health care system, to QUANTITATIVE RESEARCH
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New Zealand studies in recent years have highlighted disparities in cardiovascular disease risk management among ethnic groups, with high-risk groups over-represented in CVD mortality and morbidity statistics. However, improved management of risk factors by medication treatment is observed in the current study ensure Māori participate in easily accessible local primary health care services that improve their health, keep them well, and coordinate their ongoing care. 30 A regional Māori health action plan highlighted the importance of health education and health literacy. 9 Recent Kaupapa Māori Action Research also suggested that heart disease services must undertake work to improve Māori patients' understanding of the impact of lifestyle factors on CVR. 31 These studies underscore the need for Kaupapa Māori research that places Māori patients, and their need for excellent CVR assessment and management, at the forefront. Such research has the potential to inform the development of appropriate and effective interventions to improve CVR management among Māori in Aotearoa NZ, in order to achieve equitable CVD outcomes.
The use of clinical records as a platform to guide intervention and to close quality-of-care gaps for specific ethnicities, as applied for CDM, is similar to work undertaken in the Aboriginal and Torres Strait Islander communities in Australia. 32, 33 The Kanyini audit of randomly selected case records of indigenous Australian adults highlighted gaps in CVD risk factor screening (e.g. for cholesterol and albumin/creatinine ratio levels), as well as in prescribing and treatment gaps (e.g. 40% of people with established CVD were not prescribed combination therapy of BP medicines, statins, and antiplatelet agents). 33 The Bettering the Evaluation and Care of Health (BEACH) survey findings also demonstrated these gaps, particularly highlighting gaps in lipid measurement and treatment. 34 NZ studies in recent years have highlighted disparities in CVR management among ethnic groups, with high-risk groups overrepresented in CVD mortality and morbidity statistics. 1, 3, 6, 35 However, improved management of risk factors by medication treatment is observed in the current study; for instance, 78% of Māori patients and 70% of non-Māori patients (including Pacific and other ethnic groups) with a history of known CVD were reported to have antihypertensive therapy prescribed by their GP in 2006, 3 while 80% of all patients (Māori and non-Māori) with an assessed ≥15% CVR score had at least one antihypertensive prescription in the two-year CDM evaluation period. This suggests an improvement in proactive management of CVR, especially for those identified at risk, and also reinforces the importance of CVR assessment in high-risk populations.
The strength of this study lies in the fact that it involved analysis of a large number of Māori and Pacific general practice patients. Additionally, the data for the physiological measures in the general practice EMRs was a near-complete set, usually taken within the last 12 months. However, a number of limitations should be acknowledged. Firstly, the study involved a convenience sample of practices, and thus may not be generalisable to people enrolled at other general practices in NZ. The second limitation of this study is that there were possibly distortions of the data, due to out-of-date patient enrolment information in the EMRs, including the potential for some patients to be counted more than once if they were enrolled at more than one practice. This suggests a research opportunity to investigate the rate of such occurrences. However, of note, only one primary care provider can successfully claim the enrolment subsidy for a given patient in a given quarter, which provides an incentive for practices to keep enrolment information up to date. Anoth-
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ORIGINAL SCIENTIFIC PAPER er study limitation relates to the known problems with the quality of general practice ethnicity data, which may have led to an undercount of Māori patients in participating practices. 36 Other high-risk groups have not been separated in the current analysis, due to low caseload numbers. As recorded in the EMR, only 5% of the non-Māori population included in the study were identified as Indo-Asians. We consider this insufficient to support a separate analysis; however, there is evidence that this group is also at greater risk from CVD than NZ Europeans. 28 Further analysis of the data might also be undertaken to inform agespecific strategies for risk management, as CVD risks rise significantly with age. 37 Accurate audit of the EMR and collaboration between general practices gives a population health view of the clinical issues facing ethnic groups with serious inequities in health care. Expertise and time for population-based audit is a challenge for general practices in NZ. It is time to move to create Primary Care Research Networks and to secure these networks as places of learning, where doctors and patients in the community are united with science to search for answers that can provide a better basis for daily practice. 38 Poor medication adherence status in Māori and Pacific people represents a large gap in the way we deliver health care in NZ. Effective interventions targeting the medication adherence gaps are possible, but these can only be tested in collaborating groups of general practices and with results measured with a population health approach. Such interventions have the potential to improve the management of CVD risk factors for high-risk groups and to promote guideline-recommended CVR assessment and treatment. From a practical aspect of implementing the guideline recommendations, although screening CVR in people aged between 20 and 34 years is outside guideline recommendations, screening is frequently undertaken in high-risk groups, such as Māori and Pacific people, because of the opportunity for lifestyle education and influence.
In conclusion, general practices' EMRs have enabled assessment of the state of, and identification of gaps in, the management of CVR in Māori, Pacific and other ethnic groups in NZ.
The findings have highlighted that Māori are less likely to have a CVR assessment undertaken, and when they are assessed they are more likely to have a high CVR. There are substantial levels of poor medication adherence, particularly for cholesterol-lowering medication. More active CVR assessment, treatment and support of medication adherence in Māori attending general practices is justified, given their high mortality rate from CVD in comparison to the overall NZ population. 2 Not only is such action justifiable, it is essential to address Māori health inequities in Aotearoa NZ.
